JP2010530362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530362A5 JP2010530362A5 JP2010510239A JP2010510239A JP2010530362A5 JP 2010530362 A5 JP2010530362 A5 JP 2010530362A5 JP 2010510239 A JP2010510239 A JP 2010510239A JP 2010510239 A JP2010510239 A JP 2010510239A JP 2010530362 A5 JP2010530362 A5 JP 2010530362A5
- Authority
- JP
- Japan
- Prior art keywords
- hpv
- amino acid
- derived
- protein
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 230000000240 adjuvant Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100003729 CD40LG Human genes 0.000 claims 1
- 102100006400 CSF2 Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- GZQKNULLWNGMCW-PWQABINMSA-J lipid A(4-) Chemical compound O1[C@H](CO)[C@@H](OP([O-])([O-])=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP([O-])([O-])=O)O1 GZQKNULLWNGMCW-PWQABINMSA-J 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Claims (12)
- 皮内投与用である、ＨＰＶ関連疾患の治療又は予防用の、ＨＰＶ−Ｅ２、−Ｅ６及び／又は−Ｅ７タンパク質に由来するペプチドを含む医薬。
- 少なくとも１つのＨＬＡクラスＩＩエピトープ及び／又は少なくとも１つのＨＬＡクラスＩエピトープが、ＨＰＶ−Ｅ２、−Ｅ６及び／又はＥ７タンパク質の少なくとも１つのアミノ酸配列からの連続するアミノ酸配列内に存在する、請求項１に記載の医薬。
- 連続するアミノ酸配列の長さが、ＨＰＶ−Ｅ２、Ｅ６及び／又はＥ７タンパク質由来の１９〜４５の連続するアミノ酸残基、好ましくは２２〜４５、より好ましくは２２〜４０、より好ましくは２２〜３５、さらにより好ましくは２２、２５、２８、３２又は３５の連続するアミノ酸である、請求項１又は２に記載の医薬。
- ＨＰＶ−Ｅ２、−Ｅ６及び／又は−Ｅ７タンパク質に由来する少なくとも２種の異なるペプチドを含む、請求項１から３までのいずれか一項に記載の医薬。
- 連続するアミノ酸配列が、ＨＰＶ−Ｅ２、−Ｅ６及び−Ｅ７タンパク質の少なくとも２種、好ましくはＨＰＶ−Ｅ２、−Ｅ６及び−Ｅ７タンパク質の３種すべてのアミノ酸配列に由来する、請求項１から４までのいずれか一項に記載の医薬。
- アジュバントを含まない、請求項１から５までのいずれか一項に記載の医薬。
- 請求項１から６までに記載の１種又は複数種のペプチド及び不活性な薬学的に許容可能な担体からなる、請求項１から６までのいずれか一項に記載の医薬。
- 請求項１から５までに記載のペプチド及び少なくとも１種のアジュバントを含み、前記アジュバントは水中油に基づく乳剤に処方されておらず、及び／又は水中油型乳剤ではない、請求項１から５までのいずれか一項に記載の医薬。
- モノホスホリル脂質Ａ及び／又はＣｐＧ核酸などのＴＬＲ（３、４、７、８、９）リガンド、及び／又はＣＤ４０リガンドなどのＡＰＣ共刺激性分子、アゴニスト抗体又はそれらの機能的断片及び誘導体、及び／又はＧＭ−ＣＳＦを含む、請求項８に記載の医薬。
- ＨＰＶ関連疾患が、ＨＰＶ感染、ＨＰＶ関連悪性腫瘍、ＣＩＮ、ＶＩＮ、ＡＩＮ、ＶＡＩＮ、ＰＩＮ、子宮頸癌、外陰癌、肛門癌、頭部及び頸部の癌又は陰茎癌から選択される、請求項１から９までのいずれか一項に記載の医薬。
- 病変部位に直接皮内投与される、請求項１から１０までのいずれか一項に記載の医薬。
- 皮下投与用である、ＨＰＶ−Ｅ２、−Ｅ６及び／又は−Ｅ７タンパク質に由来するペプチドが更に含まれる、ＨＰＶ関連疾患の治療又は予防用の請求項１から１１までのいずれか一項に記載の医薬。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94107007P | 2007-05-31 | 2007-05-31 | |
| EP07109287 | 2007-05-31 | ||
| PCT/NL2008/050315 WO2009002159A2 (en) | 2007-05-31 | 2008-05-27 | Intradermal hpv peptide vaccination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014133168A Division JP5888823B2 (ja) | 2007-05-31 | 2014-06-27 | 皮内ｈｐｖペプチドワクチン接種 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010530362A JP2010530362A (ja) | 2010-09-09 |
| JP2010530362A5 true JP2010530362A5 (ja) | 2011-06-30 |
Family
ID=38477016
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510239A Pending JP2010530362A (ja) | 2007-05-31 | 2008-05-27 | 皮内ｈｐｖペプチドワクチン接種 |
| JP2014133168A Expired - Fee Related JP5888823B2 (ja) | 2007-05-31 | 2014-06-27 | 皮内ｈｐｖペプチドワクチン接種 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014133168A Expired - Fee Related JP5888823B2 (ja) | 2007-05-31 | 2014-06-27 | 皮内ｈｐｖペプチドワクチン接種 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9562075B2 (ja) |
| EP (1) | EP2155240B1 (ja) |
| JP (2) | JP2010530362A (ja) |
| CN (1) | CN101795705A (ja) |
| AU (1) | AU2008269721B2 (ja) |
| BR (1) | BRPI0812311A8 (ja) |
| CA (1) | CA2688589A1 (ja) |
| ES (1) | ES2482192T3 (ja) |
| MX (1) | MX2009012922A (ja) |
| WO (1) | WO2009002159A2 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2496916T3 (es) * | 2007-05-31 | 2014-09-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas |
| EP2344191A4 (en) * | 2008-09-02 | 2013-02-13 | Antigen Express Inc | HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE |
| EP2646459B1 (en) | 2010-12-02 | 2020-01-08 | Bionor Immuno AS | Peptide scaffold design |
| EP2883550A1 (en) * | 2013-12-12 | 2015-06-17 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Novel promiscuous HPV16-derived T helper epitopes for immunotherapy |
| WO2017075571A1 (en) | 2015-10-30 | 2017-05-04 | Children's National Medical Center | Generating hpv antigen-specific cells from a naive t cell population |
| CN108430505A (zh) | 2015-11-18 | 2018-08-21 | 免疫疫苗技术有限公司 | 包括聚肌胞苷酸多核苷酸佐剂和基于脂质的佐剂的辅助系统以及无水疫苗组合物 |
| CN117018170A (zh) * | 2016-06-20 | 2023-11-10 | Isa制药有限公司 | 肽疫苗制剂 |
| US11524063B2 (en) * | 2017-11-15 | 2022-12-13 | Arizona Board Of Regents On Behalf Of Arizona State University | Materials and methods relating to immunogenic epitopes from human papillomavirus |
| JP2021517895A (ja) * | 2018-03-12 | 2021-07-29 | スクイーズ バイオテクノロジーズ カンパニー | Ｈｐｖ関連疾患を処置するための方法 |
| TW202003019A (zh) * | 2018-03-12 | 2020-01-16 | 美商Ｓｑｚ生物科技公司 | 細胞內投遞生物分子以修改免疫反應之方法 |
| WO2019178057A1 (en) * | 2018-03-12 | 2019-09-19 | Evelo Biosciences, Inc. | Methods of treating cancer using burkholderia |
| MA52363A (fr) * | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4777239A (en) * | 1986-07-10 | 1988-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic peptides of human papilloma virus |
| US5180806A (en) * | 1988-05-16 | 1993-01-19 | The Scripps Research Institute | Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods |
| US5932412A (en) | 1990-05-11 | 1999-08-03 | Euro-Diagnostica Ab | Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes |
| DE9106105U1 (de) | 1991-05-17 | 1991-09-26 | Behringwerke Ag, 3550 Marburg | Diagnose-Kit zum Nachweis von Human-Papillomavirusinfektionen |
| US6419931B1 (en) | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| GB9505784D0 (en) * | 1995-03-22 | 1995-05-10 | Lynxvale Ltd | Anti-tumour treatment |
| WO1997023237A1 (en) | 1995-12-22 | 1997-07-03 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| ES2249907T3 (es) | 1998-05-23 | 2006-04-01 | Leiden University Medical Center | Anticuerpos de union cd40 y peptidos ctl para el tratamiento de tumores. |
| US20030118588A1 (en) | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
| US6641994B2 (en) * | 1999-08-25 | 2003-11-04 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| AU2002219711B8 (en) * | 2000-12-08 | 2006-03-02 | Academisch Ziekenhuis Leiden | Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses |
| JP2004535816A (ja) * | 2001-07-20 | 2004-12-02 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｃｉｎを含むｈｐｖ関連の前癌性増殖および癌性増殖に関する方法および組成物 |
| US6884605B2 (en) * | 2001-08-09 | 2005-04-26 | Board Of Trustees Of The University Of Arkansas | Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer |
| AU2004308964B2 (en) | 2003-12-23 | 2010-09-16 | Arbor Vita Corporation | Antibodies for oncogenic strains of HPV and methods of their use |
| US20090028874A1 (en) * | 2003-12-24 | 2009-01-29 | Leiden University Medical Center | Synthetic Protein as Tumor-Specific Vaccine |
| US8252893B2 (en) | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
| JP5106384B2 (ja) * | 2005-04-27 | 2012-12-26 | ライデン ユニバーシティ メディカル センター | Ｈｐｖ誘導性上皮内腫瘍の治療方法及び治療手段 |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
-
2008
- 2008-05-27 JP JP2010510239A patent/JP2010530362A/ja active Pending
- 2008-05-27 CA CA002688589A patent/CA2688589A1/en not_active Abandoned
- 2008-05-27 ES ES08753797.3T patent/ES2482192T3/es active Active
- 2008-05-27 MX MX2009012922A patent/MX2009012922A/es active IP Right Grant
- 2008-05-27 WO PCT/NL2008/050315 patent/WO2009002159A2/en active Application Filing
- 2008-05-27 US US12/451,983 patent/US9562075B2/en not_active Expired - Fee Related
- 2008-05-27 CN CN200880101172A patent/CN101795705A/zh active Pending
- 2008-05-27 EP EP08753797.3A patent/EP2155240B1/en not_active Not-in-force
- 2008-05-27 AU AU2008269721A patent/AU2008269721B2/en not_active Ceased
- 2008-05-27 BR BRPI0812311A patent/BRPI0812311A8/pt not_active IP Right Cessation
-
2014
- 2014-06-27 JP JP2014133168A patent/JP5888823B2/ja not_active Expired - Fee Related
-
2016
- 2016-12-16 US US15/381,367 patent/US20170143818A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530362A5 (ja) | ||
| Melief et al. | Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines | |
| Zhang et al. | Effects of astragalus polysaccharide on the immune response to foot-and-mouth disease vaccine in mice | |
| Wu et al. | Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation | |
| ES2263637T3 (es) | Hpv-e7 para el tratamiento del papilomavirus humano. | |
| CN101528255A (zh) | Hpv抗原融合蛋白疫苗组合物及其应用 | |
| Chuang et al. | Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination | |
| JP6811014B2 (ja) | Ｂ型肝炎ウイルスに対するワクチン | |
| WO2003090686A3 (en) | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality | |
| JP2013542224A5 (ja) | ||
| JP2009541373A5 (ja) | ||
| EP3199543B1 (en) | Novel peptide and use thereof | |
| Cho et al. | Advances in human papilloma virus vaccines: a patent review | |
| RU2011123700A (ru) | Нонапептид с противоопухолевой активностью | |
| RU2012136530A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2014508734A5 (ja) | ||
| Peng et al. | Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines | |
| RU2020132295A (ru) | Cpg амфифилы и их применения | |
| JP2022172244A5 (ja) | ||
| JP2010506926A5 (ja) | ||
| WO2005060993A1 (en) | Synthetic protein as tumor-specific vaccine | |
| Tseng et al. | Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination | |
| Torréns et al. | Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors | |
| CA2691091C (en) | Fusion protein, macromolecule assembled from the fusion protein, and its use in the prevention or treatment of human papillomavirus related diseases | |
| Pokorná et al. | Vaccination with human papillomavirus type 16-derived peptides using a tattoo device |